Parenteral drug delivery systems is the second most common type after oral solids and liquids. Over the last years, parenteral drugs have accounted for approximately 40% of new molecular entities approved by the U.S. Food and Drug Administration each year. Moreover, There were close to 500 parenteral drugs in the pipeline on a single year
Demand for parenteral drugs continues to increase as the overall drug market expands and new therapies for both chronic and rare diseases enter the pipeline.
How can Clariant help you to get a solution? We offer a wide range of low bioburden and low elemental impurities parenteral excipients for sensitive APIs
Parenteral application, wherever is administered subcutaneously, intramuscularly or intravenously, creates important pathways for drug delivery thanks to favorable attributes around safety and efficacy.